Wyeth Found No Signal Of Valvular Heart Disease In Diet Drug AEs - Deitch
Executive Summary
Wyeth-Ayerst identified no signal of valvular heart disease prior to 1997 in adverse drug event reports submitted for the weight loss agents Pondimin (fenfluramine) and Redux (dexfenfluramine), former Wyeth-Ayerst Senior VP-Medical Affairs Marc Deitch, MD, testified in the New Jersey diet drug class action suit.